Myungmoon Rosuvastatin Special Precautions

Talk to the doctor or pharmacist before taking Rosuvastatin Tablets: If having problem with the kidneys.
If having problem with the liver.
If taking or have taken in the last 7 days a medicine called fusidic acid, orally or by injection. The combination of fusidic acid and Rosuvastatin Tablets even lead to serious muscle problem, see Interactions.
If having had repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems with taking other cholesterol-lowering medicines. Tell the doctor immediately if unexplained muscle aches or pains occur especially if feeling unwell or having a fever. Also tell if feeling unwell or having a fever. Also tell the doctor or pharmacist if having constant muscle weakness.
If regularly drinking large amounts of alcohol.
If taking medicines used to fight the HIV infection e.g. ritonavir with lopinavir and/or atazanavir, see Interactions.
If thyroid gland is not working properly.
If over 70.
If having severe respiratory failure.
If of Asian origin.
If taking other medicines called fibrates to lower the cholesterol. Please read this monograph carefully even if other medicines for high cholesterol have been taken before.
It is recommended that liver function tests should be performed before the initiation of MYUNGMOON ROSUVASTATIN and thereafter when clinically indicated.
There has been rare postmarketing reports of cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statin. The reports are generally non-serious and reversible upon statin discontinuation with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).
Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitor in JUPITER study. There was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with a HbA1c > 6.5% at the end of the trial was significantly higher in rosuvastatin-treated versus placebo-treated patients.
MYUNGMOON ROSUVASTATIN contains Lactose: If the patient has been told by the doctor that he/she has intolerance to some sugars (lactose or milk sugar), the doctor should be contacted before taking Rosuvastatin Tablets.